FDA批准康方生物PD-1抑制剂派安普利单抗上市

医药地理
25 Apr

4月23日,美国FDA已批准康方生物的抗PD-1单抗派安普利单抗上市,联合顺铂或卡铂以及吉西他滨,用于复发或转移性非角化型鼻咽癌(NPC)成人患者的一线治疗。此外,FDA还批准了派安普利单抗单药用于接受含铂化疗及至少一种其他治疗方案后出现疾病进展的转移性非角化型鼻咽癌成人患者。派安普利单抗康方生物与正大天晴合作开发并商业化,其是采用IgG1亚型并进行Fc段改造的新型PD-1单抗。在重链Fc段利用...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10